Testing for prognosis and risk stratification

For patients affected by myelodysplastic syndrome (MDS), the need for ongoing testing is of vital importance for disease management and is recommended by both the National Comprehensive Cancer Network (NCCN) and the World Health Organization (WHO). Because treatment decisions are often based on illness severity, advanced testing can aid in diagnosis, disease monitoring, and treatment management in patients with MDS.

Mayo Clinic Laboratories’ approach to MDS testing, which aligns with NCCN and WHO recommendations, utilizes comprehensive fluorescence in situ hybridization (FISH) panels to detect for genetic biomarkers associated with disease severity, progression, and treatment response. Because all MDS testing at Mayo Clinic Laboratories is performed at one facility, the need for splitting patient samples or submitting multiple samples is diminished, while continuity of care is enhanced.

Comprehensive testing simplified

Our approach to FISH testing is designed to simplify the ordering process by providing diagnostic panels that includes all appropriate genes.

MDSDF | Myelodysplastic Syndrome (MDS), Diagnostic FISH, Varies

MDSMF | Myelodysplastic Syndrome (MDS), Specified FISH, Varies

IDHQ | IDH1 (R132) and IDH2 (R140 and R172) Quantitative Detection, Droplet Digital PCR, Varies

• Detects for mutations in IDH1 and IDH2, which are present in 4% to 12% of MDS cases.

NGSHM | MayoComplete Myeloid Neoplasms, Comprehensive OncoHeme Next-Generation Sequencing, Varies